DGKA and melanoma: Since both ritanserin and R59022 affect Type I DGKs activity at the 50 μM dose, Granade et al. searched an alternative specific for the α isoform between a library of 188 Ritanserin analogues, selecting among others the compound JNJ‐3790339 (DGKα IC50: 9.6 μM), as it resulted to be more isoform specific compared to other molecules and additionally resulted to be more cytotoxic for cancer cells, namely a melanoma, a glioblastoma multiforme and malignant T cell lines, and was able to enhance T cell activation [201], as exemplified in Figure 4.